Oncolytics Biotech (ONCY) VP buys 10,000 shares in open-market trade

Rhea-AI Filing Summary

Oncolytics Biotech Inc. VP of Product Development Allison Hagerman bought 10,000 common shares in the open market on February 12, 2026 at $0.8298 per share. After this purchase, she directly owned a total of 115,059 common shares of the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hagerman Allison

(Last) (First) (Middle)

C/O ONCOLYTICS BIOTECH INC.

4350 EXECUTIVE DRIVE, SUITE 325

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ONCOLYTICS BIOTECH INC [ ONCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Product Development

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/12/2026		P		10,000	A	$0.8298	115,059	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Kirk Look, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ONCY report for Allison Hagerman?

Oncolytics Biotech reported that VP of Product Development Allison Hagerman bought 10,000 common shares. The open-market purchase occurred on February 12, 2026, and was reported on a Form 4 insider trading filing with the U.S. Securities and Exchange Commission.

At what price did the ONCY executive buy shares on February 12, 2026?

Allison Hagerman purchased 10,000 Oncolytics Biotech common shares at $0.8298 per share. This transaction was classified as an open-market or private purchase under transaction code P on the Form 4 insider trading report filed with regulators.

How many ONCY shares does Allison Hagerman own after the reported trade?

Following the reported transaction, Allison Hagerman beneficially owned 115,059 Oncolytics Biotech common shares. The Form 4 indicates these shares are held with direct ownership, reflecting her position as VP of Product Development at the company.

Was the February 12, 2026 ONCY insider trade a purchase or a sale?

The February 12, 2026 insider trade by Allison Hagerman was a purchase. The Form 4 lists transaction code P, describing an open-market or private transaction in which she acquired 10,000 Oncolytics Biotech common shares at $0.8298 each.

What role does Allison Hagerman hold at Oncolytics Biotech (ONCY)?

Allison Hagerman is an officer of Oncolytics Biotech, serving as VP of Product Development. Her role and insider status require reporting share transactions such as the February 12, 2026 open-market purchase disclosed on the Form 4 filing.

Is Allison Hagerman’s ONCY share ownership direct or indirect?

The Form 4 indicates that Allison Hagerman’s ownership of 115,059 Oncolytics Biotech common shares is direct. The ownership code is D, and there is no noted indirect beneficial ownership or separate entity holding the reported shares on her behalf.